Theralase Technologies Inc. V.TLT

Market Cap

[enriquesuave]

A major disconnect with reality, as if we compare Market Cap of CGON which is $2.4 Billion USD, which has BTD, we would be at $6.50 US or $9 Can.  Almost unreal that we are not trading close to that range given that we are v close to BTD as well. IMHO.On top of that we have the National Microbiology Laboratory of Canada working with Ruvidar for a possible vaccine on Avian Flu and many others to come.  We also have Rutherin as an unprecedented radiosensitisor for Brain, Lung and many more cancers.  We should be at least at 20-30% of CGON's market cap now IMO or 2-3$.  All IMHO, but we are due for a major SP readjusting!

[plantrader]

Is it possible that this company simply won't be assigned credibility while on this questionable exchange, end of story? I know the FDA itself can change that, of course, but it does make me wonder if a buyout or major partnership is the only way out of this predicament. My assumption is that getting to a better exchange would probably take multiple years, and a lot of execution and delivery

[plantrader]

Edit to my comments: I mean market credibility. I wasn't referring to the science. Seems like they are accumulating scientific credibility already. But the market just doesn't care.

[Alamir1111]

Based on recent pharmaceutical acquisitions for oncology drugs and market statistics, the estimated value of the PDC upon successful completion of a FDA Phase 1/2a clinical trial ranges from $84 million to $360 million in upfront payments followed by a double digit revenue royalty stream. (Source: BIO statistic2014

[Donein25]

Alamir, Are these #s from 2014?

[Alamir1111]

I post the original news release a bit old.https://stockhouse.com/news/press-releases/2013/03/14/theralase-achieves-commercialization-milestone-for-its-bladder-cancer-therapy